PURPOSE: In adult differentiated thyroid cancer (DTC) patients, successful ablation and the number of (131)I therapies needed carry a prognostic significance. The goal was to assess the prognosis of DTC in children and adolescents treated in our centre in relation to the number of treatments needed and to establish the determinants of both complete remission (CR) and successful ablation. METHODS: Seventy-six DTC patients <21 years of age at diagnosis were included. Recurrence and death rates, rates of CR (=negative stimulated thyroglobulin, negative neck ultrasound and negative (131)I whole-body scintigraphy) and successful ablation (=CR after initial (131)I therapy) were studied. RESULTS: No patients died of DTC. Seven patients were treated by surgery alone and did not show signs of recurrence during follow-up. Of the 69 patients also treated with (131)I therapy, 47 patients achieved CR, 25 of whom had successful ablation. In multivariate analysis, female gender and the absence of distant metastases were independent determinants of a higher CR rate. Female gender, lower T stage and higher (131)I activity (successful ablation, median activity 3.1 GBq, unsuccessful ablation 2.6 GBq) were determinants of a higher rate of successful ablation. After (131)I therapy no patient showed recurrence after reaching CR or disease progression if CR was not reached. CONCLUSION: In our paediatric DTC population prognosis is extremely good with no deaths or recurrences occurring regardless of the number of (131)I therapies needed or whether CR was reached. The determinants of CR and successful ablation can be used to optimize the chance of therapy success.
PURPOSE: In adult differentiated thyroid cancer (DTC) patients, successful ablation and the number of (131)I therapies needed carry a prognostic significance. The goal was to assess the prognosis of DTC in children and adolescents treated in our centre in relation to the number of treatments needed and to establish the determinants of both complete remission (CR) and successful ablation. METHODS: Seventy-six DTC patients <21 years of age at diagnosis were included. Recurrence and death rates, rates of CR (=negative stimulated thyroglobulin, negative neck ultrasound and negative (131)I whole-body scintigraphy) and successful ablation (=CR after initial (131)I therapy) were studied. RESULTS: No patients died of DTC. Seven patients were treated by surgery alone and did not show signs of recurrence during follow-up. Of the 69 patients also treated with (131)I therapy, 47 patients achieved CR, 25 of whom had successful ablation. In multivariate analysis, female gender and the absence of distant metastases were independent determinants of a higher CR rate. Female gender, lower T stage and higher (131)I activity (successful ablation, median activity 3.1 GBq, unsuccessful ablation 2.6 GBq) were determinants of a higher rate of successful ablation. After (131)I therapy no patient showed recurrence after reaching CR or disease progression if CR was not reached. CONCLUSION: In our paediatric DTC population prognosis is extremely good with no deaths or recurrences occurring regardless of the number of (131)I therapies needed or whether CR was reached. The determinants of CR and successful ablation can be used to optimize the chance of therapy success.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Frederik A Verburg; Bart de Keizer; Cornelis J M Lips; Pierre M J Zelissen; John M H de Klerk Journal: Eur J Endocrinol Date: 2005-01 Impact factor: 6.664
Authors: H M van Santen; D C Aronson; T Vulsma; R F H M Tummers; M M Geenen; J J M de Vijlder; C van den Bos Journal: Eur J Cancer Date: 2004-07 Impact factor: 9.162
Authors: Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2009-11-29 Impact factor: 9.236
Authors: Elena-Daphne Thies; Karina Tanase; Uwe Maeder; Markus Luster; Andreas K Buck; Heribert Hänscheid; Christoph Reiners; Frederik A Verburg Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-17 Impact factor: 9.236
Authors: S Fazio; B Biondi; C Carella; D Sabatini; A Cittadini; N Panza; G Lombardi; L Saccà Journal: J Clin Endocrinol Metab Date: 1995-07 Impact factor: 5.958
Authors: Raad Alwithenani; Sarah DeBrabandere; Irina Rachinsky; S Danielle MacNeil; Mahmoud Badreddine; Stan Van Uum Journal: J Thyroid Res Date: 2019-06-02